Drug Trial Radar · NCT06998771
JSKN003 Combined Treatment of HER2-positive Gastric Cancer
Last checked: Nov 19, 2026Latest source record: May 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
153
Planned (sponsor's estimate)
Start
Jun 15, 2025
Primary completion
Jun 30, 2028
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Shanghai JMT-Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- May 31, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to evaluate the safety and efficacy of JSKN003 combination therapy as first-line treatment in HER2-positive unresectable locally advanced or metastatic gastric cancer or resectable gastric cancer.
Conditions
- HER2-positive Gastric Cancer
Interventions
JSKN003Drug
JSKN003 is administered by intravenous infusion.
KN026Drug
KN026 is administered by intravenous infusion.
CapecitabineDrug
Capecitabine is for oral administration.
EnlonstobartDrug
Enlonstobart is administered by intravenous infusion.
OxaliplatinDrug
Oxaliplatin is administered by intravenous infusion.
TrastuzumabDrug
Trastuzumab is administered by intravenous infusion.
PembolizumabDrug
Pembolizumab is administered by intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) of the first-line populationTime frame: Frame: Up to approximately 5 years
- Incidence and severity of TEAE and SAE of the first-line populationTime frame: Up to approximately 5 years
- pCR rate after neoadjuvant therapy of perioperative populationTime frame: Up to approximately 5 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.